Pfizer Inc. Hits New 52-Week High at $28.64, Reflecting Strong Performance

Pfizer Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 28.64 on April 1, 2026. This achievement underscores the company's performance in a competitive market, particularly as it navigates the complexities of the pharmaceutical landscape. Over the past year, Pfizer's stock has shown a modest increase of 1.71%, contrasting with the S&P 500's performance of 16.73%. The company boasts a substantial market capitalization of USD 255,516 million, positioning it firmly within the large-cap category. With a price-to-earnings (P/E) ratio of 15.00, Pfizer's valuation reflects its earnings potential relative to its stock price. Additionally, Pfizer offers a notable dividend yield of 286.00%, which may appeal to income-focused investors. The company's debt-to-equity ratio stands at 0.50, indicating a balanced approach to leveraging. As Pfizer continues to operate within the dynamic pharmaceutical industry, its recent stock performance highlights its current standing and resilience in the market.